A 12-year-old diagnosed with alopecia shares their experience and current treatments, including Dermovate, an unnamed cream, and liquid iron. The community offers support and encouragement.
Combining stemoxydine with topical minoxidil for hair loss treatment. Users discuss application order and effectiveness, with some skepticism about stemoxydine's benefits.
The conversation discusses using ZIX, a combination of Zinc Sulfate and Vitamin B6, for hair loss. The user is considering liquid forms for better absorption and scalp health.
The post and conversation are about a user's progress with hair loss treatments. The user has been using oral minoxidil and finasteride for several months and recently added dutasteride. They also use Nizoral shampoo. The user is happy with the results so far.
The conversation discusses using 23andme to determine if someone might respond well to minoxidil for hair loss treatment, and mentions the user's personal experience with micro-needling and minoxidil.
A user is taking 2.5 mg oral Minoxidil and was prescribed a topical oil with Minoxidil 8%, Dutasteride 0.05%, and Finasteride 0.5%. They are seeking opinions on whether this combination is excessive or appropriate.
Hair loss treatment with latanoprost, minoxidil, and biotin showed progress. Latanoprost, a glaucoma drug, stimulates anagen phase and increases conversion of vellus hair to terminal hair.
PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.
The post discusses using oral Minoxidil and Dutasteride for hair loss. Minoxidil improved hair growth with mild hypertrichosis, while Dutasteride caused severe acne, cognitive issues, and mild anxiety, leading the user to prefer Finasteride.
The user experienced significant hair growth using 0.5 mg Dutasteride and 5 mg oral Minoxidil over 10 weeks, with initial shedding but no side effects. The treatment was surprisingly affordable at $7 for a 3-month supply.
The conversation discusses hair regrowth treatments, specifically using a combination of oral and topical minoxidil, oral and topical dutasteride, and PRP. There is skepticism about the authenticity of the results, with some users questioning the changes in hair and skin appearance.
The user switched from Forhims to Numan topical treatment for hair loss, which includes finasteride, minoxidil, and azelaic acid, and is questioning the effectiveness of azelaic acid in the formula. They also mentioned that Numan has a higher concentration of minoxidil compared to their previous product.
User is 1.5 months into using oral minoxidil and finasteride for hair regrowth, along with dermarolling. They report good progress and seek advice on whether new hairs will thicken.
The user has been using 0.5 mg dutasteride and 2.5 mg oral minoxidil for a year, recently adding microneedling and topical minoxidil, with some improvement but the crown remains the weakest area. Consistency and realistic expectations are advised, as progress is slow and coverage is challenging with fine hair.
The user is experiencing an itchy scalp after six months of using dutasteride and minoxidil, suspecting dutasteride as the cause. They are seeking advice on how to alleviate the itch without stopping the treatment.
User experienced itching, redness, and hives from Minoxidil foam and is questioning if they are allergic to Minoxidil or another ingredient. They have switched to oral Finasteride.
PP405 shows promise for hair follicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.
PP405 is suspected to be a scam, with users doubting its legitimacy and effectiveness. Many recommend using proven treatments like finasteride and minoxidil.
The user is concerned about hair thinning and has been using finasteride 1mg and minoxidil 5%, along with Alpecin caffeine liquid and vitamins. Others suggest continuing the treatment, as it seems to be stabilizing the hair, and advise against stopping the medication abruptly.
Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.
User Crazy-Signature930 shares progress on oral minoxidil for eyelashes and eyebrows. Others comment on the impressive results and ask about side effects and duration of use.
The user switched from topical to oral minoxidil to improve hair regrowth but experienced significant shedding after one month. They are considering continuing oral minoxidil for six months before deciding whether to switch back to topical if no improvements occur.
A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.
Capilia Longa and Scandinavian Biolabs are discussed, with skepticism about their effectiveness and value. The conversation suggests avoiding these products due to high cost and perceived lack of results.
Latanoprost is discussed as a potential hair loss treatment, noted for its synergy with minoxidil and 5-AR inhibitors, but concerns include its effectiveness on scalp hair, cost, and potential skin darkening. Some users express interest in trying latanoprost or bimatoprost despite limited real-world evidence.
Brian Dye's theory links skeletal malocclusion type II to hair loss, suggesting it's a blood flow issue. Treatments mentioned include minoxidil, finasteride, and anti-inflammatory drugs like benaxoprofen.
The conversation discusses using tretinoin as an additional treatment for hair loss alongside minoxidil, with plans to test its effectiveness by applying it to only one side of the scalp. The user intends to start this experiment after using minoxidil for a year.
The conversation is about a user trying a 0.2% Alfatrafiol treatment for hair loss, combined with Kx826, Minoxidil, microneedling, and ketoconazole. The user reports reduced itching and discusses sourcing the treatment.
PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.